peroxisome proliferator-activated receptor delta (PPARδ) agonist. Seladelpar 10 mg. Caps: 30 X 10 mg
Recomm. dose: 10 mg once daily.
For prim. biliary cholangitis (PBC) in combin. with ursodeoxycholic acid (UDCA) in adlts who have an inadequate resp. to UDCA alone, or as monother. in those unable to toler. UDCA.
C/I: Hypersens.
Antivirals. Bulevirtide 2 mg/ml. Vial. Pwder. for sol. for inj. 30 X 2 mg
Manage the underlying hepatitis B virus (HBV) infect. simultan. according to the official guidelines. To be admin. 1/d by SC inject. Recomm. dosage is 2 mg 1/d as long as clin. benef. is seen.
Tmt.of chronic hepatitis delta virus (HDV) infect. in plasma (or serum) HDV-RNA posit. adults with compensated liver dis.
C/I: Hypersens.
Drug class Cross-linked polyacrylic acid sodium salt, hydroxy propyl
methyl cellulose (HPMC), titanium dioxide, cellulose acetate
phthalate, hydroxypropyl cellulose, chitosan, diethyl
phthalate, polyvinyl alcohol polyethylene copolymer
(Kollicoat), triethyl citrate, cellulose acetate, acetyl tributyl
citrate.
Caps. X 56
1 cap. before meal X 2/d
Reducing BW in pts with 25 < BMI < 40 in conjunction with diet and exercise.
C/I: Hypersens. Pregn
Corticosteroid. Budesonide 2 mg. Canister with 14 X of 1.2 g
One actuation of 2 mg /d
Tmt of act. ulcerative colitis limited to the rectum and the sigmoid colon
C/I: Hypersens. /hepatic cyrrhosis
Anti-CD20, Human Monoclonal Antibody. Ocrelizumab 40 mg/ml. Vial. 1 X 920 mg for SC inject.
single 23 mL in the abdomen over approx. 10 minutes every 6 months.
For adults with relapsing or primary progress. forms of multiple sclerosis.
C/I:Hypersens. Active HBV infection/ A hist. of life-threatening admin. reaction to ocrelizumab
Sodium Chloride 5%. Eye drops. solut., 10 ml
To use as needed
* Visual discomfort, burning and eye irritat. caused by corneal oedema
* In the case of abnormal fluid accumulat. caused by corneal oedema, with or without inflamm. or blunt trauma after refractive or ophthalmic surgery, cataracts, transplants, retinal detachments, corneal transplants, corneal endothelial decompensation and in all dystrophic, mechanical, toxic and inflammatory corneal decompensations.
אימונותרפיה המכוונת נגד קטפסין-D מעוררת גם תגובה חיסונית מולדת וגם תגובה חיסונית נרכשת כנגד גידולי סרטן השד
אימלונסטרנט עם או ללא אבמציקליב בסרטן שד מתקדם
מדדי טריגליצרידים-גלוקוז כגורם מנבא לאירועים כבדיים בסוכרת
חוויות מטופלים, בני משפחה ואחיות בטיפול אונקולוגי אמבולטורי
פסיכוזה חדשה? מתי לחשוד ב-NMDAR encephalitis
כושר גופני ותפקוד כלי דם קטנים במתבגרים עם סוכרת סוג 1
מחקרים רב מרכזיים הדור הבא: השפעת מודלי שפה גדולים
השפעת וריקוצלה קלינית על תוצאי הריון ולידות חי
לעלון לצרכן לחצו כאן
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
Antivirals. Bulevirtide 2 mg/ml. Vial. Pwder. for sol. for inj. 30 X 2 mg
Manage the underlying hepatitis B virus (HBV) infect. simultan. according to the official guidelines. To be admin. 1/d by SC inject. Recomm. dosage is 2 mg 1/d as long as clin. benef. is seen.
Tmt.of chronic hepatitis delta virus (HDV) infect. in plasma (or serum) HDV-RNA posit. adults with compensated liver dis.
C/I: Hypersens.
Urinary Tract Analgesic. Phenazopyridine (as HCl) 100 mg. TABS: 30. Adult and children over 12
years: 2 drugs. 3 x dly. Aft. meals.
Children from 6 to 12 years: 12mg/kg
bdy wt divided into 3 daily doses.
Relief pain, burning, urgency.
C/I: G6PD deficiency, renal insuffic.
hepatic insuffic., hepatitis, hypersens.
peroxisome proliferator-activated receptor delta (PPARδ) agonist. Seladelpar 10 mg. Caps: 30 X 10 mg
Recomm. dose: 10 mg once daily.
For prim. biliary cholangitis (PBC) in combin. with ursodeoxycholic acid (UDCA) in adlts who have an inadequate resp. to UDCA alone, or as monother. in those unable to toler. UDCA.
C/I: Hypersens.
Bile Acid Preparations. Cholic Acid 50, 250 mg. CAPS.:90. Tmt. of inborn errors of prim. bile acid synthesis is 10-15 mg/kg/d, either as a single dly. dose or in divid. doses, for both adult and paed. pts. The dose should be subseq. titrated to the desired effect but should not exceed a max. of 15mg/kg/d. Where the dose calcul. is not a multiple of 50, the nearest dose below the max. of 15mg/kg/d should be select., provided that is suffic. to suppress urin. bile acids. If not, the next higher dose should be select. Pts. with concom. familial hypertriglyceridemia is 11 to 17 mg/kg once dly. or in two divid. doses and is adjust. based on clin. response.
Tmt. of infants, child., adolesc. aged 1m.-18 yrs. and adults of inborn errors in prim. bile acid synthesis due to Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) defic., 2- (or α-) methylacyl-coa racemase (AMACR) defic., Cholesterol 7α -hydroxylase (CYP7A1) defici., 3β-hydroxy-5-C27-steroid oxidoreductase defic.,(also known as 3β-hydroxy-5-C27-steroid dehydrogenase/isomerase or 3β-HSD or HSD3β7.
C/I: Hypersens. Concom. use with phenobarbital.
Cannabinoids, Specific Immunoglobulin. Palvizumab 50 mg, 100 mg. VIAL(PWDR) + DILUENT: 1 X 50 mg+ 4 ml
diluent, 100 mg + 10 ml diluent.
15 mg/kg by I.M. inject. 1 x mthly
during course of RSV season. See lit.
Preven. of serious lower resp. tract dis.
requir. hospitalis. caused by RSV in child.
at high risk for RSV dis.:
Child. born at 35 wks. of gestation or less
and less than 6 mths. of age at the onset
of the RSV season. Child. less than 2 yrs. of age and requir.
tmt. for bronchopulm. dysplasia within
the last 6 mths.
Children less than 2 yrs. of age and with
haemodyn. signif.congen. heart dis.
C/I: Hypersens. to palvizumab or any
compon. of formula, or other humanized
monoclonal antibodies.
Nicotine Receptor Partial Agonist. Varenicline (as tartrate) 0.5 mg, 1 mg. Health basket inclusion: Champix will be given to the treatment of smoking cessation parallel to supportive means.
TABS: 55 x 0.5 mg, 56 x 1 mg; starter pack: 11 x 0.5 mg + 14, 28 x 1 mg.
Days 1 – 3: 0.5 mg ×1/d.
Days 4– 7: 0.5 mg ×2/d.
Day 8 – end of tmt.: 1 mg ×2/d.
Pts. should be treated with Varenicline for 12 wks. For pts. who have successf. stopped smok. at the end of 12 wks., an addit. course of 12 wks. tmt. with Varenicline is recomm. to further incr. the likelihood of long-term abstinence.
Pts. with ren. impair. No dosage adjust. is necessary for pts. with mild- moder. renal impair. For pts. with sev. renal impair. (estimated CrCl <30 mL/min), the recomm. start. dose of Varenicline is 0.5 mg ×1/d. The dose may then be titrated as needed to a max. dose of 0.5 mg×2/d. For pts. with end-stage renal dis. underg. hemodialysis, a max. dose of 0.5 mg mg×/d may be admin. if toler.
Aid to smoking cessat. for adults over 18
yrs.
C/I: Hypersens., known skin react. to varenicline
Corticosteroid, Vitamin D Analogue. Betamethasone (as dipropionate) 0.5 mg/g, Calcipotriol (as monohydrate) 50 mcg/g. ALUMINIUM CAN:60 g.
Enstilar foam should be applied to the affected area once dly. The recom. tmt. period is 4 wks. The dly. max. dose should not exceed 15 g, i.e. one 60 g can should last for at least 4 d. 15 g corresponds to the amount admin. from the can if the actuator is fully depressed for approx. one minute. A two-second application delivers approx. 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly correspond. to the surface area of an adult hand. Concomit. use with other topic. products contain. calcipotriol in addition to Enstilar: the total dose of all calcipotriol contain. products should not exceed 15 g/d. The total bdy. surf. area treated should not exceed 30%.
Ren. / hep. impair. The safety and efficacy in pts. with severe renal insuffic. or severe Hep. disord. have not been evaluated.
Ped. population:The safety and efficacy in child. below 18 yrs. have not been establish. Enstilar is not indic. for child<18 yrs. of age.
Topical tmt. of psoriasis vulgaris in adults.
C/I: Hypersens.
Pts. with erythrodermic and pustular psorias.
Pts. with known calcium metabolism disord.
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Corticosteroid. Fluticasone Propionate 0.05%. METERED NASAL SPRAY: 120 doses. 2
sprays into ea. nostril 1 x dly. Child:
4-12 yrs: 1 spray into ea. nostril 1 x dly.
Under 4 yrs: Not recommended.
Proph. and tmt. seasonal allerg. rhinit.
incl. hayfever, perennial rhinit.
C/I: Hypersens. Concomitt. use with HIV drugs.
